Literature DB >> 8886613

Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.

M Czerwinski1, J P Gibbs, J T Slattery.   

Abstract

Busulfan is eliminated by glutathione S-transferase (GST)-catalyzed conjugation with glutathione (GSH). We have characterized the busulfan-conjugating activity of purified human liver GSTA1-1, GSTA1-2, GSTA2-2, GSTM1-1, and placental GSTP1-1. Isoforms were purified from cytosol by GSH-affinity chromatography and chromatofocusing. In addition, the busulfan-conjugating activity of cDNA-expressed GTH1 and GTH2, corresponding to GSTA1-1 and GSTA2-2, were characterized. The major product of busulfan conjugation, a thiophenium ion (THT+), was assayed by GC/MS after conversion to tetrahydrothiophene (THT). THT+ formation rate increased linearly with busulfan concentration up to its solubility limit for all GST isoforms. Because Vmax and KM could not be determined separately, the slope of the velocity vs. substrate concentration plot, Vmax/KM was used to compare isoform activities. Vmax/KM for GSTA1-1 was 7.95 microliters/min/mg protein, the highest busulfan-conjugating activity of all human liver and placenta isoforms evaluated. GSTM1-1 and GSTP1-1, respectively, had 46% and 18% of the activity of GSTA1-1. Since the polymorphic mu-class GST catalyzed busulfan conjugation, we examined busulfan clearance in 50 patients undergoing high-dose busulfan before bone marrow transplantation. Busulfan clearance was normally distributed, suggesting that GSTM1-1 does not contribute significantly to the elimination of busulfan from the body. We conclude that GSTA1-1 is the major isoform catalyzing busulfan conjugation, whereas GSTM1-1 and GSTP1-1 may be important in the protection of specific cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886613

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Developmental and activity-dependent expression of LanCL1 confers antioxidant activity required for neuronal survival.

Authors:  Chao Huang; Mina Chen; Dejiang Pang; Dandan Bi; Yi Zou; Xiaoqiang Xia; Weiwei Yang; Liping Luo; Rongkang Deng; Honglin Tan; Liang Zhou; Shouyang Yu; Liheng Guo; XiaoXia Du; Yiyuan Cui; Jiahua Hu; Qing Mao; Paul F Worley; Bo Xiao
Journal:  Dev Cell       Date:  2014-08-25       Impact factor: 12.270

2.  The busulfan metabolite EdAG irreversibly glutathionylates glutaredoxins.

Authors:  Michele Scian; William M Atkins
Journal:  Arch Biochem Biophys       Date:  2015-08-14       Impact factor: 4.013

3.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

4.  Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.

Authors:  Sandi L Navarro; Timothy W Randolph; Laura M Shireman; Daniel Raftery; Jeannine S McCune
Journal:  J Proteome Res       Date:  2016-07-20       Impact factor: 4.466

5.  Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction.

Authors:  Arthur J L Cooper; Islam R Younis; Zoya V Niatsetskaya; Boris F Krasnikov; John T Pinto; William P Petros; Patrick S Callery
Journal:  Drug Metab Dispos       Date:  2008-05-12       Impact factor: 3.922

Review 6.  Pharmacogenetics of cancer therapy: getting personal.

Authors:  E Y Krynetski; W E Evans
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 7.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

8.  Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.

Authors:  Francesca Bonifazi; Gianluca Storci; Giuseppe Bandini; Elena Marasco; Elisa Dan; Elena Zani; Fiorenzo Albani; Sara Bertoni; Andrea Bontadini; Sabrina De Carolis; Maria Rosaria Sapienza; Simonetta Rizzi; Maria Rosa Motta; Martina Ferioli; Paolo Garagnani; Michele Cavo; Vilma Mantovani; Massimiliano Bonafè
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

9.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

10.  Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.

Authors:  Keiji Shinozuka; Hongwei Tang; Roy B Jones; Donghui Li; Yago Nieto
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-29       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.